Key result
Chronic therapy with the selective endothelin A receptor antagonist LU135252 partially prevented angiotensin II-induced hypertension and alterations of endothelial function in rats (P < .05).
Why the study?
Does LU135252 reduce blood pressure and improve endothelial function in rats with angiotensin II-induced hypertension?
Population
Rats with angiotensin II-induced hypertension (200 ng/kg per minute)
Comparison
Selective endothelin A receptor antagonist… vs Placebo or angiotensin II alone
Design
Preclinical
Follow-up
2 weeks
Authors
Loading...
No clinical implications in hypertension; leaves open translation of ET_A blockade from rat models.
Does LU135252 reduce blood pressure and improve endothelial function in rats with angiotensin II-induced hypertension?
p-value: p=<.05
Chronic ET_A-receptor blockade with LU135252 partially prevents angiotensin II-induced hypertension and endothelial dysfunction in a rat model.
d’Uscio et al. (1997) studied Angiotensin II-induced hypertension. LU135252 vs. Placebo / Angiotensin II alone was evaluated on Systolic blood pressure and endothelial function (p=<.05). Chronic therapy with the selective endothelin A receptor antagonist LU135252 partially prevented angiotensin II-induced hypertension and alterations of endothelial function in rats (P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: